Shots:
- Novartis has reported the topline P-III (RemIND) trial data assessing remibrutinib (PO) vs PBO in adults with CIndU inadequately controlled by H1-antihistamines
- Trial met its 1EP for the three prevalent subtypes of CIndU, incl. symptomatic dermographism, cold urticaria, & cholinergic urticaria, delivering significantly higher complete response rates at Wk. 12
- Additionally, Novartis has submitted an sNDA to the US FDA seeking approval of remibrutinib for symptomatic dermographism, with full data to be filed globally in the coming mos. & P-III trial results to be presented in the future
Ref: Novartis | Image: Novartis | Press Release
Related News: Novartis Reports Final P-III (ALIGN) Trial Data on Vanrafia (Atrasentan) in IgA Nephropathy (IgAN)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
